Related Experiment Video
Updated: Aug 12, 2026

Preclinical Assessment of the Bioactivity of the Anticancer Coumarin OT48 by Spheroids, Colony Formation Assays, and Zebrafish Xenografts
Published on: June 26, 2018
Quercetin as an Adjuvant in Cancer Therapy: Biological Mechanisms, Oral Delivery Systems, and Clinical Perspectives
Sofia Melchior1, Ionela Codruta Bubuianu2, Sonia Calligaris3
1Department of Human Sciences and Promotion of the Quality of Life, San Raffaele University, Via Val Cannuta 247, 00166, Rome, Italy.
Introduction:
Cancer remains a major global health challenge, and quercetin, a widely distributed dietary flavonoid, has attracted increasing attention for its anti-inflammatory, antioxidant, and neuroprotective properties in oncology research.
Methods:
This narrative review synthesizes recent preclinical and clinical evidence on quercetin for cancer prevention and treatment, with an emphasis on its adjuvant role, toxicity-modulating effects, and formulation strategies designed to improve delivery.
Results:
Quercetin has been reported to enhance the activity of several chemotherapeutic agents by modulating apoptosis, drug-resistance mechanisms, and key signaling pathways; moreover, it may reduce treatment-related nephrotoxicity, cardiotoxicity, reproductive toxicity, and neurotoxicity. Nevertheless, clinical translation remains limited by poor aqueous solubility, reduced stability, rapid metabolism, and low bioavailability. In addition, clinical trial data remain sparse, and many completed studies have not yet reported outcomes.
Discussion:
Consequently, advances in delivery systems, including nanoformulations, liposomes, and micelles, may improve quercetin stability, absorption, and tumor targeting.
Conclusion:
Overall, quercetin appears to be a promising adjunct in oncology; however, stronger clinical evidence and optimized delivery strategies are required to define its therapeutic value.
More Related Videos
Related Concept Videos
Cancer Prevention
Some...
Cancer Therapies
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
Targeted Cancer Therapies
There are several types of targeted therapies against specific...
Tumor Immunotherapy
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase
Oral Drug Delivery Systems: Introduction

